AR085905A1 - A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PANCREAS CANCER - Google Patents

A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PANCREAS CANCER

Info

Publication number
AR085905A1
AR085905A1 ARP120100840A ARP120100840A AR085905A1 AR 085905 A1 AR085905 A1 AR 085905A1 AR P120100840 A ARP120100840 A AR P120100840A AR P120100840 A ARP120100840 A AR P120100840A AR 085905 A1 AR085905 A1 AR 085905A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical combination
treatment
pancreas cancer
rfde
synergistic pharmaceutical
Prior art date
Application number
ARP120100840A
Other languages
Spanish (es)
Inventor
Veena Agarwal
Arun Balakrishnan
Kalpana Joshi
Giridharan Periyasamy
Maggie Rathos
Somesh Sharma
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Publication of AR085905A1 publication Critical patent/AR085905A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Reivindicación 1: Una combinación farmacéutica que comprende un inhibidor QDC seleccionado de los compuestos de la fórmula (1), en donde Ar es un grupo fenilo, que está no sustituido o sustituido por 1, 2, ó 3 sustituyentes idénticos o diferentes seleccionados de: halógeno; nitro, ciano, alquilo C1-4, trifluorometilo, hidroxilo o alcoxi C1-4; o una sal o un solvato farmacéuticamente aceptable de los mismos; y un compuesto capaz de inhibir la actividad quinasa del receptor de factor de desarrollo epidérmico (RFDE).Reivindicación 7: La combinación farmacéutica de acuerdo con la reivindicación 1, en donde el compuesto capaz de inhibir la actividad quinasa del receptor del factor de desarrollo epidérmico (RFDE) se selecciona de erlotinib o lapatinib. Reivindicación 10: La combinación farmacéutica de acuerdo con la reivindicación 1; en donde la mencionada combinación asimismo comprende gemcitabina.Claim 1: A pharmaceutical combination comprising a QDC inhibitor selected from the compounds of the formula (1), wherein Ar is a phenyl group, which is unsubstituted or substituted by 1, 2, or 3 identical or different substituents selected from: halogen; nitro, cyano, C1-4 alkyl, trifluoromethyl, hydroxyl or C1-4 alkoxy; or a pharmaceutically acceptable salt or solvate thereof; and a compound capable of inhibiting the kinase activity of the epidermal development factor receptor (RFDE). Claim 7: The pharmaceutical combination according to claim 1, wherein the compound capable of inhibiting the kinase activity of the epidermal development factor receptor (RFDE) is selected from erlotinib or lapatinib. Claim 10: The pharmaceutical combination according to claim 1; wherein said combination also includes gemcitabine.

ARP120100840A 2011-03-14 2012-03-14 A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PANCREAS CANCER AR085905A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161452197P 2011-03-14 2011-03-14

Publications (1)

Publication Number Publication Date
AR085905A1 true AR085905A1 (en) 2013-11-06

Family

ID=45999898

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100840A AR085905A1 (en) 2011-03-14 2012-03-14 A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PANCREAS CANCER

Country Status (3)

Country Link
AR (1) AR085905A1 (en)
TW (1) TW201242597A (en)
WO (1) WO2012123889A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11007174B2 (en) * 2013-07-12 2021-05-18 Piramal Enterprises Limited Pharmaceutical combination for the treatment of melanoma
ES2873959T3 (en) 2014-05-28 2021-11-04 Piramal Entpr Ltd Pharmaceutical combination comprising a CDK inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer
WO2017160568A1 (en) 2016-03-16 2017-09-21 Eli Lilly And Company Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer
KR20210013155A (en) * 2018-05-23 2021-02-03 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Use of CDK4/6 inhibitors in combination with EGFR inhibitors in the manufacture of medicaments for the treatment of tumor diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
IL77133A (en) 1984-12-04 1991-01-31 Lilly Co Eli Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation
JP2757348B2 (en) 1996-04-18 1998-05-25 株式会社同仁化学研究所 New water-soluble tetrazolium salt compound
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
EP2026805A1 (en) * 2006-05-08 2009-02-25 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
BRPI0621777A2 (en) 2006-06-21 2013-03-12 Piramal Life Sciences Ltd enantiomerically pure flavone derivatives for the treatment of proliferative disorders and processes for their preparation
WO2008007169A1 (en) 2006-07-07 2008-01-17 Piramal Life Sciences Limited An enantioselective synthesis of pyrrolidine-substituted flavones
EP2116246A1 (en) 2007-01-19 2009-11-11 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
KR101403100B1 (en) 2007-05-15 2014-06-19 피라말 라이프 사이언시스 리미티드 A synergistic pharmaceutical combination for the treatment of cancer
TWI461194B (en) * 2009-05-05 2014-11-21 Piramal Entpr Ltd Pyrrolidine Substituted Flavones as Radio Sensitizers

Also Published As

Publication number Publication date
WO2012123889A1 (en) 2012-09-20
TW201242597A (en) 2012-11-01

Similar Documents

Publication Publication Date Title
AR078163A1 (en) USE OF AMINODIHYDROTIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES
CR20150045A (en) HEPATITIS C INHIBITORS
AR088175A1 (en) 3-PIRIMIDIN-4-IL-OXAZOLIDIN-2-USEFUL WAVES TO TREAT CANCER AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CU24621B1 (en) SUBSTITUTED BICYCLIC HETEROCYCLIC COMPONENTS AS PRMT5 INHIBITORS
AR094314A1 (en) 3-CINASA PHOSFATIDYLINOSITOL INHIBITORS
DOP2015000158A (en) PRMT5 INHIBITORS AND THEIR USES
UY32490A (en) BETA-SECRETASA INHIBITORS
CR20110224A (en) PIRAZOLOPIRIMIDINA INHIBITOR JAK COMPOUNDS AND METHODS
EA201492170A1 (en) NEW CYPRIDE N-PYRIDINYLAMIDES SUBSTITUTED AS A KINAZ INHIBITOR
AR093244A1 (en) SUBSTITUTED BENZENE COMPOUNDS USED IN THE TREATMENT OF EZH2-DISORDERS
AR064561A1 (en) DERIVATIVES OF 2-AZA-BICYCLE [3.1.0] HEXANE AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES RELATED TO GENERAL DYSFUNCTIONS OF THE OREXINE SYSTEM.
ECSP12011645A (en) JAK DE PIRAZOLOPIRIMIDINA INHIBITING COMPOUNDS AND METHODS
AR063602A1 (en) DERIVATIVES OF SPIROINDOLINONE, PHARMACEUTICAL FORMULATIONS THAT CONTAIN THEM AND THEIR USE IN THE OBTAINING OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ONCOLOGICAL DISORDERS.
ECSP12011910A (en) IMIDAZOPIRIDINE DERIVATIVES AS JAK INHIBITORS
EA201301209A1 (en) PYRROLOTRIAZINON DERIVATIVES AS P13K INHIBITORS
BR112012001817B8 (en) furazanobenzimidazoles, their use, production process and pharmaceutical composition
AR080596A1 (en) RENTAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
BR112016028814A2 (en) pharmaceutical composition, methods of treating a disease or condition, inhibiting immune reactions or overgrowth or destructive cancer cell proliferation, kit, compound, a salt, an isomer, or a pharmaceutically acceptable mixture thereof, and, use of a compound, a salt, an isomer, or a pharmaceutically acceptable mixture thereof?
ES2657549T3 (en) Substituted pyridopyrazines as new SYK inhibitors
EA201101334A1 (en) NEW COMPOUNDS BENZOTIADIAZEPINA, METHOD OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING
AR086100A1 (en) CHROMENONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR093408A1 (en) DERIVATIVES OF OXAZOLIDIN-2-ONA-PYRIMIDINE
EA201490754A1 (en) DERIVATIVES OF CARBAMATE / URINE, CONTAINING PIPERIDINE AND PIPERAZINE RINGS AS RECEPTOR INHIBITORS
CO6362013A2 (en) RIFAMYCIN DERIVATIVES
EA201591645A1 (en) NANTAGONISTS WITH PHENOXYPYPERIDINE NUCLEUS IN STRUCTURE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal